Successful recovery from severe COVID-19 pneumonia after kidney transplantation : The interplay between immunosuppression and novel therapy including tocilizumab
© 2020 Wiley Periodicals LLC..
Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 22(2020), 5 vom: 30. Okt., Seite e13334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lauterio, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2020 Date Revised 31.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.13334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310314038 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310314038 | ||
| 003 | DE-627 | ||
| 005 | 20231225135828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.13334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310314038 | ||
| 035 | |a (NLM)32449235 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lauterio, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful recovery from severe COVID-19 pneumonia after kidney transplantation |b The interplay between immunosuppression and novel therapy including tocilizumab |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2020 | ||
| 500 | |a Date Revised 31.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Valsecchi, Mila |e verfasserin |4 aut | |
| 700 | 1 | |a Santambrogio, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a De Carlis, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Merli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Calini, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Centonze, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Buscemi, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Bottiroli, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Puoti, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Fumagalli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a De Carlis, Luciano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 22(2020), 5 vom: 30. Okt., Seite e13334 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:5 |g day:30 |g month:10 |g pages:e13334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.13334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 5 |b 30 |c 10 |h e13334 | ||